Tricyclo Ring System Having The Diazine Ring As One Of The Cyclos Patents (Class 544/344)
-
Patent number: 7638513Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-? or combinations thereof.Type: GrantFiled: December 1, 2005Date of Patent: December 29, 2009Assignee: Schering CorporationInventors: M. Arshad Siddiqui, Umar Faruk Mansoor, Panduranga A. Reddy, Vincent S. Madison
-
Publication number: 20090298842Abstract: Described herein is the discovery that certain mycobacterial serine/threonine protein kinases, particularly protein kinase G (PknG), are effective therapeutic targets for the treatment of mycobacterial infections. Furthermore, the present application refers to the use of mycobacterial serine/threonine protein kinases for developing methods for detection and determination of these kinases for recognizing and monitoring diseases and for controlling therapy of diseases.Type: ApplicationFiled: August 1, 2009Publication date: December 3, 2009Inventors: János Pató, György Kéri, László Örfi, Frigyes Wáczek, Zoltán Horváth, Péter Banhegyi, Istaván Szabadkai, Jenö Marosfalvi, Bálint Hegymegi-barakonyi, Zsolt Székélyhidi, Zoltán Greff, Axel Choidas, Gerald Bacher, Andrea Missio, Anil Koul
-
Patent number: 7626019Abstract: Disclosed are processes for the preparation of fused piperazin-2-one derivatives of general formula (I) wherein the groups R1 to R5, A1 and A2 have the meanings given in the claims and in the description, particularly the preparation of 7,8-dihydro-5H-pteridin-6-one derivatives and intermediates thereof.Type: GrantFiled: May 16, 2007Date of Patent: December 1, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Adil Duran, Guenter Linz
-
Publication number: 20090258862Abstract: Compounds of the formula (I): as well as pharmaceutically acceptable salts and solvates are disclosed. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.Type: ApplicationFiled: August 25, 2006Publication date: October 15, 2009Inventors: Steven L. Colletti, Hong Shen, James R. Tata, Michael J. Szymonifka
-
Publication number: 20090238761Abstract: This invention provides novel aryl piperazine derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D3, D2-like and 5-HT2 receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders incl. schizophrenia.Type: ApplicationFiled: January 2, 2006Publication date: September 24, 2009Applicant: Universita Degli Studi Di SienaInventors: Giuseppe Campiani, Stefania Butini, Caterina Fattorusso, Francesco Trotta, Silvia Franceschini, Meri De Angelis, Karin Sandager Nielsen
-
Publication number: 20090215786Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.Type: ApplicationFiled: July 26, 2006Publication date: August 27, 2009Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frederic Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Remi Delansorne, Stefania Vallese, Matteo Colombo
-
Publication number: 20090192147Abstract: The invention relates to [a]-fused indole compounds of the Formula II, or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein. The invention also relates to compositions comprising the compounds of Formula II, and methods for making and using the compounds.Type: ApplicationFiled: January 30, 2009Publication date: July 30, 2009Applicant: WyethInventors: Semiramis Ayral-Kaloustian, Nan Zhang, Aranapakam Mudumbai Venkatesan, Tarek Suhayl Mansour, Thai Hiep Nguyen, James Thomas Anderson
-
Patent number: 7563793Abstract: This invention provides estrogen receptor modulators having the structure: wherein R1 to R7, R9, R10, X, Y, and Z are as defined in the specification; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 16, 2005Date of Patent: July 21, 2009Assignee: WyethInventors: Joseph Peter Sabatucci, Fei Ye, Paige Erin Mahaney
-
Patent number: 7550464Abstract: The present invention provides a novel a condensed polycyclic compound useful as a phosphodiesterase 4 inhibitor, which is shown by the formula [I]: or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.Type: GrantFiled: September 6, 2006Date of Patent: June 23, 2009Assignee: Mitsubishi Tanbe Pharma CorporationInventors: Tatsuzo Ukita, Yoshihiro Terakawa, Kazuteru Wada, Aya Nakata, Atsuko Sakai, Koji Ogawa
-
Publication number: 20090156583Abstract: The present invention relates to compounds of formula I wherein A, G, r and R1 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: ApplicationFiled: February 20, 2009Publication date: June 18, 2009Inventors: Matthias Nettekoven, Jean-Marc Plancher, Hans Richter, Olivier Roche, Sven Taylor
-
Publication number: 20090093489Abstract: Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.Type: ApplicationFiled: October 5, 2007Publication date: April 9, 2009Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Nouri Neamati, Antonio Garofalo
-
Publication number: 20090093476Abstract: The present invention provides new compounds displaying high affinity for adenosine A3 receptors. It also provides modulators of adenosine A3 receptors. It further provides compounds for the treatment and/or prophylaxis of conditions and diseases where adenosine A3 receptor plays a role. Pharmaceutical compositions for the treatment and/or prophylaxis of conditions and diseases where adenosine A3 receptors play a role are also described.Type: ApplicationFiled: December 19, 2006Publication date: April 9, 2009Applicant: FAUST PHARMACEUTICALSInventors: Stephan Schann, Stanislas Mayer, Sophie Gardan
-
Patent number: 7511041Abstract: The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-? inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-? activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis.Type: GrantFiled: September 18, 2003Date of Patent: March 31, 2009Assignee: Bayer Pharmaceuticals CorporationInventors: Mitsuyuki Shimada, Toshiki Murata, Kinji Fuchikami, Hideki Tsujishita, Naoki Omori, Issei Kato, Mami Miura, Klaus Urbahns, Florian Gantner, Kevin Bacon
-
Publication number: 20090062265Abstract: Tricyclic nitrogen containing compounds and their use as antibacterials.Type: ApplicationFiled: March 29, 2007Publication date: March 5, 2009Inventors: Graham Elgin Jones, Timothy James Miles, Neil David Pearson
-
Patent number: 7476465Abstract: An object of the present invention is to provide a battery which is high in capacity density and superior in stability. An electrode containing a compound having a diazine-N,N?-dioxide structure shown by a general formula (1) described below as an electrode active material is used, where x, y, x?, and y? independently shows integer numbers of 0 or more respectively, and the order of condensation of diazine rings and benzene rings may be alternate or random. One of substituents R1, R2, R3, R4, Ra, Rb, Rc, and Rd shows a part of main chain or side chain of oligomer or polymer, and the other independently shows hydrogen atom, halogen atom, or a specific group.Type: GrantFiled: February 18, 2003Date of Patent: January 13, 2009Assignee: NEC CorporationInventors: Yukiko Morioka, Masahiro Suguro, Kentaro Nakahara, Jiro Iriyama, Shigeyuki Iwasa, Masaharu Satoh
-
Patent number: 7417145Abstract: An intermediate compound for total synthesis of ecteinascidins comprising, a compound represented by general formula 2 having thioether group at C4 site, and the substituent R2 of N12 site is trichloroethoxicarbonyl (Troc) to which various substituents can be introduced by mild condition, further having a 10-membered ring structure which can be converted to a ring of other numbered members.Type: GrantFiled: September 20, 2002Date of Patent: August 26, 2008Assignee: Japan Science and Technology AgencyInventors: Tohru Fukuyama, Toshiyuki Kan
-
Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them
Publication number: 20080188460Abstract: Compounds of formula (I): wherein A represents a 5, 6 or 7-membered (hetero)aromatic or non-aromatic ring, n and n? represent 0, 1 or 2 X represents an alkylene chain as defined in the description, R3 represents an aryl or heteroaryl group, one of the groups R1 and R2 represents a hydrogen atom and the other represents a group of formula (II) as defined in the description. Medicinal products containing the same which are useful in treating conditions involving a defect in apoptosis.Type: ApplicationFiled: January 24, 2008Publication date: August 7, 2008Applicant: LES LABORATOIRES SERVIERInventors: Patrick Casara, Thierry Le Diguarher, Olivier Geneste, John Hickman -
Publication number: 20080166593Abstract: The present invention relates to the use of certain organic compounds comprising fused aromatic compounds in organic electronic devices, in particular electroluminescent devices.Type: ApplicationFiled: March 20, 2006Publication date: July 10, 2008Inventors: Philipp Stoessel, Holger Heil, Horst Vestweber
-
Publication number: 20080161315Abstract: The present invention is concerned with novel indol-3-yl-carbonyl-piperidine-benzopyrrolone, -benzoxazolone and -benzotriazole derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. In particular, the present invention is concerned with compounds of formula (I) wherein X, Y and R1 to R10 are as described in the specification.Type: ApplicationFiled: December 19, 2007Publication date: July 3, 2008Inventors: Caterina Bissantz, Christophe Grundschober, Raffaello Masciadri, Hasane Ratni, Mark Rogers-Evans, Patrick Schnider
-
Publication number: 20080161292Abstract: Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed.Type: ApplicationFiled: December 27, 2007Publication date: July 3, 2008Applicant: Abbott LaboratoriesInventors: Vincent L. Giranda, Julie M. Miyashiro, Thomas D. Penning, Keith W. Woods
-
Publication number: 20080161316Abstract: The present invention is concerned with novel indol-3-yl-carbonyl-piperidine-benzopyrrolone, -benzoxazolone and -benzotriazole derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. In particular, the present invention is concerned with compounds of formula (I) wherein X, Y and R1 to R10 are as described in the specification.Type: ApplicationFiled: December 19, 2007Publication date: July 3, 2008Inventors: Caterina Bissantz, Christophe Grundschober, Raffaello Masciadri, Hasane Ratni, Mark Rogers-Evans, Patrick Schnider
-
Publication number: 20080132513Abstract: The invention relates to certain fused ring compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.Type: ApplicationFiled: September 25, 2007Publication date: June 5, 2008Applicant: Synta Pharmaceuticals Corp.Inventors: Quinglin Che, Nha Huu Vo, Shoujun Chen
-
Patent number: 7371861Abstract: The present invention relates to an improved process for preparing ring-fluorinated aromatics of the general formula (I) by a halogen exchange reaction (halex reaction) of a plurality of halogen substituents in one stage in the presence of a catalyst.Type: GrantFiled: July 6, 2005Date of Patent: May 13, 2008Assignee: LANXESS Deutschland GmbHInventors: Axel Pleschke, Albrecht Marhold
-
Patent number: 7355340Abstract: The present invention is to provide quinoxaline derivatives, which have excellent electron transportation and hole blocking properties, and which can be formed into a film without being crystallized. According to the invention, quinoxaline derivatives represented by the general [formula 1] are synthesized. (wherein X and Y represent a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, and R1 to R6 represent individually hydrogen, an alkyl group, an alkoxyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group. Further, an organic semiconductor device including an electroluminescent device containing the foregoing quinoxaline derivatives is formed.Type: GrantFiled: November 13, 2003Date of Patent: April 8, 2008Assignee: Semiconductor Energy Laboratory Co., Ltd.Inventors: Satoko Shitagaki, Hiroko Yamazaki, Satoshi Seo
-
Patent number: 7273869Abstract: The present invention is directed to compounds comprising a ring-fused quinoxalinyl moiety which inhibit the activity of Akt, a serine/threonine protein kinase.Type: GrantFiled: April 4, 2003Date of Patent: September 25, 2007Assignee: Merck & Co., Inc.Inventors: Craig W. Lindsley, Zhijian Zhao
-
Patent number: 7253281Abstract: The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.Type: GrantFiled: June 28, 2005Date of Patent: August 7, 2007Assignees: Hoffmann-La Roche Inc., Vernalis Research LimitedInventors: Jonathan Mark Bentley, Paul Hebeisen, Patrizio Mattei, Marc Muller, Hans Richter, Stephan Roever, Sven Taylor
-
Patent number: 7250511Abstract: Cyclopenta[g]quinazolines of formula (I), and esters and amides thereof may be made by reacting an ester or amide of formula (II); or a protected derivative thereof with a complex containing the (propargyl)Co2(CO)6+ionType: GrantFiled: August 30, 2002Date of Patent: July 31, 2007Assignee: BTG International LimitedInventor: Vassilios Bavetsias
-
Patent number: 7244843Abstract: The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.Type: GrantFiled: October 5, 2004Date of Patent: July 17, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Dean A. Wacker, Jeffrey G. Varnes
-
Patent number: 7230139Abstract: The present invention relates to Diterpenoid Compounds, compositions comprising an effective amount of a Diterpenoid Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering an effective amount of a Diterpenoid Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, or for inducing apoptosis in a cancer or neoplastic cell. The compounds, compositions, and methods of the invention are further useful for treating or preventing a fungal infection. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a fungus.Type: GrantFiled: June 10, 2004Date of Patent: June 12, 2007Assignee: Gemin X BiotechnologiesInventors: Jean-Francois Lavallee, Terrence W. Doyle, Elise Rioux, Laurent Belec, Daniel Rabouin, Xavier Billot, Samuel Fortin
-
Patent number: 7217844Abstract: The present invention relates to Diterpenoid Compounds, compositions comprising an effective amount of a Diterpenoid Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering an effective amount of a Diterpenoid Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, or for inducing apoptosis in a cancer or neoplastic cell. The compounds, compositions, and methods of the invention are further useful for treating or preventing a fungal infection. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a fungus.Type: GrantFiled: December 1, 2003Date of Patent: May 15, 2007Assignee: Gemin X BiotechnologiesInventors: Pierre Beauparlant, Giorgio Attardo, Zhiying Zhang, Angela M. Stafford, Rosa Ubillas, James B. McAlpine, Jean-Francois Lavallee, Samuel Fortin, Sasmita Tripathy
-
Patent number: 7208490Abstract: The invention includes tetrahydroquinoline and related compounds of formula I, and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogensType: GrantFiled: October 2, 2003Date of Patent: April 24, 2007Assignee: Pharmacia & Upjohn Company LLCInventors: Michael Robert Barbachyn, Gordan L. Bundy, Paul Joseph Dobrowolski, Alexander Ross Hurd, Gary E. Martin, Dennis Joseph McNamara, John Raymond Palmer, Donna L. Romero, Arthur Glenn Romero, J. Craig Ruble, Debra Ann Sherry, Lisa Marie Thomasco, Peter Laurence Toogood
-
Patent number: 7189724Abstract: The invention provides substituted quinoxalines having the general formulas where R1, R2, R3, and R4 are, inter alia, alkyl, aryl, or heteroaryl groups; Z is NH or O; and X is, inter alia, COOH or CONH2. The compounds of the invention have antiviral and immunomodulatory activity and are useful for treating infectious diseases, particularly viral infections.Type: GrantFiled: April 15, 2004Date of Patent: March 13, 2007Assignee: Valeant Research and DevelopmentInventors: Haoyun An, Frank Rong, Jim Wu, Clayton Harris, Suetying Chow
-
Patent number: 7160732Abstract: The present invention is directed, in part, to fluorescein-based ligands for detection of metal ions, and methods of making and using the same.Type: GrantFiled: July 9, 2001Date of Patent: January 9, 2007Assignee: Massachusetts Institute of TechnologyInventors: Stephen J. Lippard, Shawn Burdette, Scott Hilderbrand, Roger Y. Tsien, Grant K. Walkup
-
Patent number: 7153859Abstract: The present invention provides a novel a condensed polycyclic compound useful as a phosphodiesterase 4 inhibitor, which is shown by the formula [I]: or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.Type: GrantFiled: July 31, 2002Date of Patent: December 26, 2006Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Tatsuzo Ukita, Yoshihiro Terakawa, Kazuteru Wada, Aya Nakata, Atsuko Sakai, Koji Ogawa
-
Patent number: 7145009Abstract: Chemical compounds of formula (I): and pharmaceutically acceptable salts and addition compounds and prodrugs thereof are useful in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes inspidus, and sleep apnea.Type: GrantFiled: October 16, 2003Date of Patent: December 5, 2006Assignee: Vernalis Research LimitedInventors: David Reginald Adams, Jon Mark Bentley, James Davidson, Matthew Alexander James Duncton, Richard Hugh Phillip Porter
-
Patent number: 6960587Abstract: Compounds of the general structural formula (I), and use of the compounds and salts and solvates thereof, as therapeutic agents.Type: GrantFiled: October 9, 2001Date of Patent: November 1, 2005Assignee: Lilly Icos LLCInventors: Mark W. Orme, Lisa M. Schultze, Jason Scott Sawyer
-
Patent number: 6953791Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.Type: GrantFiled: February 21, 2003Date of Patent: October 11, 2005Assignee: Pfizer, Inc.Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
-
Patent number: 6933387Abstract: The present invention is directed to 1,2,3,4,10,10a-hexahydropyrazino [1,2-a]indole derivatives of formula (I): as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein the substituents have the meanings provided in the specification. Compounds of the present invention may be used in the treatment or prevention of obesity or Type II diabetes.Type: GrantFiled: March 25, 2003Date of Patent: August 23, 2005Assignees: Hoffmann-La Roche Inc., Vernalis Research LimitedInventors: Jonathan Mark Bentley, Paul Hebeisen, Marc Muller, Hans Richter, Stephan Roever
-
Patent number: 6930104Abstract: The object of the present invention is to provide soluble ?-amyloid precursor protein secretory stimulators, which are effective in treating neurodegenerative diseases as well as cerebrovascular disorder-induced neuronopathy. More specifically, the present invention provides a novel compound of the following Formula (I) or a salt or prodrug thereof: [wherein R1 and R2 each represent a hydrogen atom or a lower alkyl group, etc., Ar1 and the ring B each represent an optionally substituted aromatic group, the ring A represents an optionally substituted benzene ring, the ring C represents an optionally substituted 4- to 8-membered ring which may further be condensed with an optionally substituted ring, X represents CH or N, and Y represents CH or N].Type: GrantFiled: April 25, 2002Date of Patent: August 16, 2005Assignee: Takeda Chemical Industries, Ltd.Inventors: Mitsuru Kakihana, Kaneyoshi Kato, Masaaki Mori, Toshiro Yamashita
-
Patent number: 6844345Abstract: The present invention provides piperazine derivatives in accordance with formula (I) as well as salts, hydrates and esters thereof. The substituent designations are as provided in the specification. The compounds of the present invention can be used in the treatment of type II diabetes or obesity.Type: GrantFiled: March 7, 2002Date of Patent: January 18, 2005Assignees: Hoffman-La Roche Inc., Vernal Research LimitedInventors: Paul Hebeisen, Patrizio Mattei, Marc Muller, Hans Richter, Stephan Roever, Sven Taylor
-
Publication number: 20040204418Abstract: The present invention provides a novel a condensed polycyclic compound useful as a phosphodiesterase 4 inhibitor, which is shown by the formula [I]: 1Type: ApplicationFiled: February 6, 2004Publication date: October 14, 2004Inventors: Tatsuzo Ukita, Yoshihiro Terakawa, Kazuteru Wada, Aya Nakata, Atsuko Sakai, Koji Ogawa
-
Patent number: 6800627Abstract: Chemical compounds of formula (I): and pharmaceutically acceptable salts and addition compounds and prodrugs thereof are useful in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes inspidus, and sleep apnea.Type: GrantFiled: October 9, 2001Date of Patent: October 5, 2004Assignee: Vernalis Research LimitedInventors: David Reginald Adams, Jon Mark Bentley, James Davidson, Matthew Alexander James Duncton, Richard Hugh Phillip Porter
-
Patent number: 6780862Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I): Sag-Tag (I) or a pharmaceutically acceptable salt thereof, wherein Sag and Tag are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep and sexual disorders, migraine and other conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.Type: GrantFiled: December 19, 2001Date of Patent: August 24, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Albert J. Robichaud, Ian S. Mitchell
-
Patent number: 6756376Abstract: The present invention provides a compound having sPLA2 inhibiting activity. The compound represented by the formula (I): wherein E is N or C—R4; G is N or C—R25; R1 is a carbocyclic group, heterocyclic group or the like; one of R3 and R4 is —(L2)-(acidic group), the other is a hydrogen atom, wherein L2 is a group connecting with an acid group; A ring is optionally substituted 5-8 membered cyclohexane ring or cyclohexene ring; R24 and R25 are a hydrogen atom or the like, its prodrug, their pharmaceutically acceptable salt, or hydrate thereof.Type: GrantFiled: May 9, 2002Date of Patent: June 29, 2004Assignee: Shionogi & Co., Ltd.Inventors: Masahiro Fuji, Tetsuo Okada, Makoto Adachi
-
Patent number: 6703401Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by clear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).Type: GrantFiled: November 27, 2001Date of Patent: March 9, 2004Assignees: Novo Nordisk A/S, Dr. Reddy's Research FoundationInventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
-
Patent number: 6703385Abstract: The present invention provides a compound having sPLA2 inhibiting activity. The compound represented by the formula (I): wherein R1 is (a) C1 to C20 alkyl, C2 to C20 alkenyl, C2 to C20 alkynyl, carbocyclic groups, heterocyclic groups or the like; R2 is COCONH2 or the like; Q1 is a nitrogen atom or C—R4; one of R3 and R4 is —(L2)-(acidic group) wherein L2 is a group connecting with an acid group and the length of the connecting groups 1 to 5 atoms, and the other is a hydrogen atom; R21 and R22 are hydrogen atoms or the like; X is —CR23R24— or the like wherein R23 and R24 are hydrogen atoms or the like; Y is —CR25R26— or the like wherein R25 and R26 are hydrogen atoms or the like; Z is CH2 or the like; a broken line ( - - - ) represents the presence or absence of a bond, its prodrug, their pharmaceutically acceptable salt, or solvate thereof.Type: GrantFiled: January 22, 2002Date of Patent: March 9, 2004Assignee: Shionogi & Co., Ltd.Inventors: Mitsuaki Ohtani, Masahiro Fuji, Makoto Adachi, Tomoyuki Ogawa
-
Publication number: 20040038978Abstract: Compounds of the general structural formula (I), and use of the compounds and salts and solvates thereof, as therapeutic agents.Type: ApplicationFiled: April 9, 2003Publication date: February 26, 2004Inventors: Mark W. Orme, Lisa M. Schultze, Jason Scott Sawyer
-
Publication number: 20040019040Abstract: Compounds of Formula I or a pharmaceutically acceptable salt thereof are provided: 1Type: ApplicationFiled: April 24, 2003Publication date: January 29, 2004Applicant: WyethInventors: P. Sivaramakrishnan Ramamoorthy, Robert E. McDevitt
-
Publication number: 20040009970Abstract: Compounds of Formula I or a pharmaceutically acceptable salt thereof are provided: 1Type: ApplicationFiled: April 24, 2003Publication date: January 15, 2004Applicant: WyethInventor: P. Sivaramakrishnan Ramamoorthy
-
Publication number: 20040006063Abstract: This invention is directed to compounds of the formula 1Type: ApplicationFiled: February 21, 2003Publication date: January 8, 2004Inventors: Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker